托吡酯对帕金森病中左旋多巴诱导的运动障碍的作用  

The effect of topiramate on levodopa-induced dyskinesia in Parkinson's disease

作　　者：程冬敏 吴保鑫 马正磊[1] 叶新春 王妍[1] 石彦彦[1] 张孝良[1] 

机构地区：[1]沛县人民医院神经内科,江苏沛县221600

出　　处：《中国实用神经疾病杂志》2017年第24期87-90,共4页Chinese Journal of Practical Nervous Diseases

基　　金：国家自然科学基金青年项目(81201025)

摘　　要：目的评估托吡酯对左旋多巴诱导的运动障碍的作用。方法纳入50例左旋多巴治疗合并运动障碍患者,随机分成对照组和托吡酯组,托吡酯组在原治疗的基础上给予托吡酯,4周内逐渐增加至100mg/d,并持续应用2周。结果治疗6周后,托吡酯组与对照组及0周相比,通过AUC测量的运动障碍加重,差异有统计学意义(P<0.05)。5例因耐受差退出研究。结论托吡酯倾向于使PD合并左旋多巴诱导的运动障碍患者运动症状恶化,且耐受性较差。Objective To evaluate the effect of topiramate into patients with Parkinson ＆#39;s disease and levodopa-induced dys-kinesia .Methods Fifty patients with Parkinson＆#39;s disease and stable levodopa-induced dyskinesia were randomized into the topira-mate group and control group .The topiramate group was treated with topiramate with the original treatment .The study medication was titrated to 100 mg/day over four weeks ,and assessments were carried out after a further two weeks .Results After 6 weeks of treatment ,patients taking topiramate showed a significant increase in dyskinesia severity compared to control group and 0-week （P〈0.05） .5 patients withdrew from the study whilst taking topiramate due to adverse effects .Conclusion Topiramate tended to worsen dyskinesia in patients with Parkinson＆#39;s disease ,and was poorly tolerated .

关 键 词：帕金森病 托吡酯 AMPA受体拮抗剂 左旋多巴诱导 运动障碍 

分 类 号：R742.5[医药卫生—神经病学与精神病学]